Navigation Links
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
Date:1/17/2011

STANFORD, Calif. Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction (heart attack).

The findings were published online in Cardiovascular Revascularization Medicine and will be presented at The Sixth International Conference on Cell Therapy for Cardiovascular Disease at Columbia University Medical Center, New York City, on January 20, 2011.

Platelet-rich plasma (PRP) has been identified as a novel biologic treatment for wound healing and sports-related injuries. Studies indicate PRP stimulates cell repair via growth factor release and by attracting reparative cells. Only recently, however, have scientists begun to study PRP's potential in repairing damaged cardiovascular tissue.

Working with colleagues at Stanford University Medical Center, lead author Allan Mishra, MD, a leading PRP researcher, studied the effects of RevaTen PRP (a proprietary formulation of concentrated platelets and white blood cells) on cardiac function after inducing cardiac ischemia (damage to myocardial tissue caused by blood restriction) in mice. The research was conducted under the direction of Robert Robbins, MD, chairman of the department of cardiothoracic surgery at Stanford University.

In this study of 28 mice, researchers induced ischemia by either permanently occluding the left anterior descending artery (Group A) or temporarily ligating it for 45 minutes (Group B). The hearts were then injected with RevaTen PRP or saline control. In order to assess cardiac function after treatment, magnetic resonance images were taken at seven days post-procedure (Group A) and 21 days (Group B). Tissue from all hearts was collected for histopathologic evaluation.

In both groups, mice that received PRP after ischemia had significantly better cardiac function as measured by left ventricular ejection fraction on MRI than those that had been injected with saline only. In group A, the RevaTen-treated animals had 38% better ejection fraction compared to saline controls. In group B, the RevaTen-treated animals had 28% improvement in ejection fraction compared to controls. Additionally, less scar tissue was found in RevaTen-treated hearts than in controls.

"Although this is an observational study using an animal model, PRP might someday be employed at the point of care to treat patients who have had a heart attack. This could preserve cardiac function and limit the progression to congestive heart failure," Dr. Mishra says. "Since myocardial infarction remains the leading cause of death in industrial nations, RevaTen PRP may become a powerful biologic tool in fighting heart disease and provide cost savings." The authors caution that this is a preclinical study and that further translational research is needed to understand how RevaTen PRP might work to repair and/or protect cardiovascular tissue.


'/>"/>

Contact: Patti Davis
patti@davismedpr.com
630-920-8042
DAVIS MEDPR, Inc.
Source:Eurekalert

Related biology news :

1. How Toxoplasma gondii gets noticed
2. Plasma produces KO cocktail for MRSA
3. Modeling Toxoplasma focus of workshop
4. Toxoplasma gondii spreads in the habitat of the Iberian lynx
5. Atmospheric pressure plasma jet from a grounded electrode
6. Grant advances quark-gluon plasma studies

7. Scripps Research scientists redefine the role of plasma cells in the immune system
8. MIT researchers study the danger of toxoplasma parasites
9. Long-term study shows effect of climate change on animal diversity
10. New approach to treating cystic fibrosis lung infection shows promise
11. Research shows Brazilian acai berry antioxidants absorbed by human body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology: